

Keywords: colorectal cancer; screening; FOBt; endoscopy; participation; uptake

Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women

R G Blanks^{*1}, V S Benson¹, R Alison¹, A Brown¹, G K Reeves¹, V Beral¹, J Patnick^{1,2} and J Green¹

¹Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK and ²NHS Cancer Screening Programmes, Public Health England, Fulwood House, Old Fulwood Road, Sheffield S10 3TH, UK

Background: In 2006, the National Health Service Bowel Cancer Screening Programme in England (NHSBCSP) began offering routine population-based biennial faecal occult blood testing (FOBt) at ages 60–69. There is, however, limited information on how characteristics of individuals affect participation and outcomes of screening, and we studied this association by linking NHSBCSP data to a large prospective cohort of women.

Methods: Electronic linkage of the NHSBCSP and Million Women Study records identified 899 166 women in the study cohort with at least one invitation for screening. NHSBCSP provided information on screening acceptance, FOBt results, screen-detected colorectal cancer and other outcomes. The Million Women Study provided prospectively collected information on personal and lifestyle factors. Multiple regression was used to estimate relative risks (RRs) of factors associated with acceptance and outcomes of screening.

Results: Overall, 70% of women (628 976/899 166) accepted their first invitation for bowel cancer screening, of whom 9133 (1.5%) were FOBt-positive, 743 (0.1%) had screen-detected colorectal cancer and 3056 (0.5%) had screen-detected colorectal adenoma. Acceptance was lower in women from the most than the least deprived tertile, in South Asians and in Blacks than in Whites, in current than in never smokers and in obese than in normal weight women: adjusted RRs (95% confidence interval) for acceptance vs not, 0.90 (0.90–0.90); 0.77 (0.75–0.79); 0.94 (0.92–0.96); 0.78 (0.77–0.78); and 0.88 (0.88–0.89), respectively: $P < 0.001$ for each. These factors were also associated with an increased risk of being FOBt-positive and of having screen-detected adenoma, but were not strongly associated with the risk of screen-detected colorectal cancer. Relative risks for screen-detected adenoma were 1.22 (1.12–1.34), 2.46 (1.75–3.45), 1.61 (1.05–2.48), 1.53 (1.38–1.68) and 1.77 (1.60–1.95), respectively ($P < 0.001$ for all, except for Blacks vs Whites $P = 0.03$). Use of hormone therapy for menopause was associated with reduced risk of screen-detected adenoma, RR ever vs never use, 0.87 (0.81–0.93), $P < 0.001$ and colorectal cancer, 0.78 (0.68–0.91), $P = 0.001$.

Interpretation: Among women in England, socioeconomic and lifestyle factors strongly affect participation in routine bowel cancer screening, risk of being FOBt-positive and risk of having screen-detected colorectal adenoma. However, screen-detected colorectal cancer risk is not strongly related to these factors.

In 2006, a population-based nationwide organised screening programme, the National Health Service Bowel Cancer Screening Programme (NHSBCSP), began offering those aged 60–69 years routine biennial faecal occult blood testing (FOBt), with follow-up diagnostic testing for those positive for FOBt (www.cancerscreening.nhs.uk/bowel). Acceptance of bowel cancer screening in the

*Correspondence: Dr R Blanks; E-mail: roger.blanks@ceu.ox.ac.uk

Received 11 September 2014; revised 16 January 2015; accepted 27 January 2015; published online 5 March 2015

© 2015 Cancer Research UK. All rights reserved 0007–0920/15

NHSBCSP has been shown to increase with age, to be greater in women than in men and to be lower in populations more deprived than the average (von Wagner *et al*, 2011; Lo *et al*, 2014). Existing studies have largely used routinely collected screening data, with limited information on individual characteristics of the invited or screened population other than age, sex and residence. Little is known about how other characteristics of individuals affect participation in bowel screening, or how lifestyle and other factors affect FOBt positivity and the risk of having screen-detected colorectal cancer. Recent reviews point out that despite evidence, recommendations and availability of screening tests, uptake for screening is disappointingly low (The Lancet, 2014).

Linkage of the NHSBCSP and an ongoing large population-based UK cohort, the Million Women Study, offers the opportunity to study individual lifestyle factors affecting participation and outcomes of routine bowel cancer screening. Here we investigate the associations between prospectively collected personal characteristics and screening acceptance, FOBt positivity and the risk of screen-detected colorectal cancer and adenoma.

MATERIALS AND METHODS

The NHSBCSP collects individual data on invitations, acceptance and FOBt results. For those who are FOBt-positive, findings of further investigations are also recorded by the NHSBCSP. In 2006–2010, the NHSBCSP sent biennial invitation letters to men and women aged 60–69 years who were registered with the National Health Service (NHS) (after 2010 the age range was extended to 60–74). About 2 weeks after the invitation letter, a FOBt kit is sent by mail, with instructions on how to use the kit, and return it to the screening programme. Those who test FOBt-positive are invited for further diagnostic tests, which can include colonoscopy (the default test, used for the great majority), flexible sigmoidoscopy and radiological investigations. Outcomes for these analyses are as follows: uptake (acceptance) of screening (defined in the screening programme as a record of a completed FOBt within 13 weeks of invitation); FOBt positivity; completion of a diagnostic test following screening; and diagnosis of screen-detected colorectal adenoma or invasive cancer.

The Million Women Study cohort includes 1.2 million women from England recruited in 1996–2001 through NHS breast screening clinics. Women completed a questionnaire about sociodemographic, medical and lifestyle factors, and provided signed consent for linkage to their medical records. The study has ethical approval from Oxford and Anglia Multi-Centre Research Ethics Committee (now Cambridge South Research Ethics Committee). Details of the study design have been published (Million Women Study Collaborative Group, 1999 and 2003) and questionnaires can be viewed at www.millionwomenstudy.org.

Population available for the linkage study. The 1.2 million women from England taking part in the Million Women Study were aged between 55 and 74 years (average 64 years) in 2006, when the NHS began to roll out the bowel-screening programme across the country. Those women in the Million Women Study in the target age group of 60–69 (60–74 after 2010) at or after the start of the bowel-screening programme in their residential area will have received such an invitation, and have a record in the bowel-screening system; they form the population eligible for data linkage and subsequent analysis. In this study only the first invitation to bowel screening for each individual is considered.

Data linkage. Electronic linkage was performed in 2013 by NHS Connecting for Health (now part of the Health and Social Care Information Centre), using NHS number and date of birth of Million Women Study participants recruited in England, provided by the study investigators. Detailed information on those who had

been invited to screening by the NHSBCSP was then sent to the Million Women Study investigators, and linked for analysis with prospectively collected personal characteristics recorded in study participants. Approval for linkage was given by the Cambridge South Research Ethics Committee and by the NHS Bowel Cancer Screening Programme Research Committee.

Statistical analysis. All analyses refer to the first invitation sent by NHSBCSP. Multiple regression methods were used. To study factors associated with acceptance of screening, we calculated adjusted risk ratios, referred to here as relative risks (RRs), and 95% confidence intervals (CIs) for acceptance (that is, returning a completed FOB test kit) *vs* not (mostly by not returning a completed FOBt kit, but sometimes by declining to participate after receiving the initial letter of invitation). For study factors associated with FOBt positivity, with undergoing subsequent diagnostic testing and with clinical diagnoses we calculated adjusted RRs and 95% CIs among those who returned a completed FOBt kit; had a positive FOB test result; or had undergone diagnostic testing, as appropriate.

Analyses were adjusted as appropriate by socioeconomic status (tertiles of the Townsend deprivation index (Townsend *et al*, 1988), ethnicity (White, Black and South Asian), smoking status (never, past and current), body mass index (BMI; <25, 25–29.9, 30 + kg m⁻²), parity (nulliparous and parous), past use of oral contraceptives (never and ever), use of hormone therapy (HT) for the menopause (never and ever), strenuous exercise (<1, 1 + times per week), alcohol intake (<20 g, ≥20 g per week), region of residence, age at invitation (<61.9, 62–63.9, 64–65.9, 66–67.9 and 68 + years) and year of birth (1930–1944 and 1945–1959). Women with missing values for any of the adjustment variables (<2% in all categories other than ethnicity, which was unknown for 9% of women invited to screening) were assigned to a separate category for that variable. Information on variables was as reported at the Million Women Study recruitment except for ethnicity, which was derived from the ethnic group self-reported by women responding to a resurvey questionnaire sent ~3 years after recruitment, and/or ethnicity as recorded for hospital admissions, as previously described (Gathani *et al*, 2014). Scores for the Townsend Index of Deprivation were assigned by postcode at recruitment according to Enumeration District (ED) of the 1991 Census; EDs contain on average some 200 households/500 people, and are the smallest available area for which a measure of deprivation is available in England (<http://www.ons.gov.uk/ons/guide-method/census/census-2001/glossary/a-g/index.html>).

Role of the funding source. Funders did not influence the contents of the paper or its submission.

RESULTS

A total of 899 166 Million Women Study participants received at least one invitation from the NHSBCSP for screening. We report results for the first invitation to screening only. Invited women had been sent their first invitation for routine bowel cancer screening between 7 December 2006 and 28 March 2012. Their mean age at first invitation was 65.3 (s.d. 3.6) years. Of the 899 166 women invited, 628 976 (70%) accepted the invitation by completing an FOB test. Of the 270 190 women who did not accept, 17 851 declined to receive a FOBt kit after the initial invitation letter, 250 748 were sent a kit but did not return it and 1591 returned at least one kit but did not complete the process (spoilt kit, technical failure, failure to respond to further kits and did not complete the process for other reason). Characteristics of the women who accepted or did not accept bowel cancer screening are shown in Table 1; and Table 2 shows adjusted RRs for acceptance of bowel cancer screening *vs* nonacceptance. Acceptance was significantly

Table 1. Characteristics of Million Women Study participants by acceptance of first invitation for screening by the NHS Bowel Cancer Screening Programme in England

	Bowel-screening accepted (N = 628 976)	Bowel-screening not accepted (N = 270 190)	Total invited for screening (N = 899 166)
Mean age at first invitation to bowel screening, years (s.d.)	65.2 (3.6)	65.3 (3.8)	65.3 (3.6)
Socioeconomic group (% in upper third)	36	28	33
Current smoker, %	17	31	21
Body mass index ≥ 30 kg m ⁻² , %	16	22	18
Ever had full-term pregnancy, %	90	89	90
Ever used oral contraceptives, %	66	62	65
Ever used HT, %	55	50	53
Strenuous physical activity ≥ 1 times per week, %	42	35	40
Alcohol intake ≥ 20 g per week, %	49	42	47

Abbreviation: HT = hormone therapy for menopause.

Table 2. Adjusted^a RRs and 95% CIs for acceptance of screening in 899 166 women invited to bowel cancer screening

	n Cases accepted/invited	RR (95% CI)
Socioeconomic level (tertiles)		
Least deprived	225 928/299 952 (75%)	1.00
Medium	213 066/296 443 (72%)	0.98 (0.97–0.98)
Most deprived	185 246/296 097 (63%)	0.90 (0.90–0.90)
Ethnic group		
White	571 645/800 958 (71%)	1.00
Black	2234/3598 (62%)	0.94 (0.92–0.96)
South Asian	2783/5375 (52%)	0.77 (0.75–0.79)
Smoking status		
Never	319 603/430 627 (74%)	1.00
Past	176 156/240 928 (73%)	0.98 (0.98–0.98)
Current	99 159/176 939 (56%)	0.78 (0.77–0.78)
Body mass index (kg m⁻²)		
< 25	294 937/402 658 (73%)	1.00
25–29	211 025/300 104 (70%)	0.97 (0.96–0.97)
30 +	95 471/151 090 (63%)	0.88 (0.88–0.89)
Full-term pregnancy		
Never	64 403/94 204 (68%)	1.00
Ever	563 797/803 588 (70%)	1.04 (1.03–1.04)
Oral contraceptive use		
Never	212 320/312 617 (68%)	1.00
Ever	411 766/578 068 (71%)	1.02 (1.02–1.02)
HT use		
Never	281 419/415 220 (68%)	1.00
Ever	341 919/474 460 (72%)	1.04 (1.04–1.05)
Strenuous exercise		
< 1 Per week	353 722/522 151 (68%)	1.00
1 + Per week	257 287/346 552 (74%)	1.04 (1.04–1.04)
Alcohol (g per week)		
< 20	321 029/474 789 (68%)	1.00
20 +	304 526/418 087 (73%)	1.04 (1.03–1.04)
Region		
South	302 043/428 801 (70%)	1.00
Midlands	141 596/198 368 (71%)	1.03 (1.02–1.03)
North	185 337/271 997 (68%)	0.99 (0.99–0.99)

Abbreviations: CI = confidence interval; HT = hormone therapy for menopause; RR = relative risk.
^aAdjusted by age at invitation and calendar year categories, and all other factors listed above as appropriate.

(*P* < 0.001) lower in women from the most deprived than the least deprived tertile of the population, RR 0.90, (95% CI 0.90–0.90); in South Asian and in Black than White women: RRs 0.77 (95% CI 0.75–0.79) and 0.94 (95% CI 0.92–0.96), respectively; in current than never smokers, 0.78 (95% CI 0.77–0.78); and in obese women

than those with a normal BMI, 0.88 (95% CI 0.88–0.89). Acceptance was slightly higher in parous women and in those who reported more frequent strenuous physical activity, drank more alcohol and had used HT for menopause.

Table 3 summarises the outcome of the screening FOBT in those who accepted. Of the 628 976 women who completed the FOB test, 9133 (1.5%) had a positive FOBT result and were referred for further diagnostic tests. Most of those referred attended for diagnostic testing (87%; 7911 out of 9133), and diagnostic test results were recorded for all but 17 women. Colonoscopy was the sole diagnostic test in 91% of those tested. Colorectal cancer was diagnosed in 743 women (0.1% of all women screened, 8% of those who were FOBT-positive and 9% of those who had a diagnostic test) and 3056 were diagnosed with colorectal adenoma (0.5% of all women screened, 33% of those who were FOBT-positive and 39% of those who completed a diagnostic test). Only 13 women with colorectal cancer also had reported screen-detected adenoma, and they are included just in analyses relating to cancer. Of those who had a diagnostic test result, 2214 (28%) had only a condition other than neoplasia recorded; the most common specific other diagnoses were diverticular disease and haemorrhoids. In almost a quarter of those who were FOBT-positive (1881, 24%), the diagnostic test record identified no abnormality.

Table 4 shows the RRs and 95% CIs for being FOBT-positive, and for having a diagnosis of colorectal cancer or colorectal adenoma, in those screened. FOBT positivity was most strongly associated with deprivation, Non-White ethnicity, smoking and obesity. These factors were also associated with an increased risk of having screen-detected adenoma. Relative risks in the most vs least deprived tertile, South Asian and Black vs White ethnicity, current vs never smokers and obese vs not, for screen-detected adenoma were 1.22 (1.12–1.34), 2.46 (1.75–3.45), 1.61 (1.05–2.48), 1.53 (1.38–1.68) and 1.77 (1.60–1.95), respectively. Being physically active, parous and having used menopausal HT were associated with small reductions in the risk of having a screen-detected adenoma.

Risk factors for screen-detected colorectal cancer were often not the same as for screen-detected adenoma. There was no significant association with deprivation, smoking or obesity (numbers in subgroups by ethnicity were too small to allow reliable analysis). The only statistically significant association was a decreased risk associated with ever use of menopausal HT: RR 0.78 (0.68–0.91), *P* = 0.001.

The 13% of women (1222 out of 9133) who were FOBT-positive but had no further diagnostic tests within the screening programme were more likely than those who had diagnostic tests to be current smokers or of South Asian ethnicity (Table 5). Some of these women are known to have refused further tests; however, for over half, the reason for not having diagnostic tests is not

Table 3. Outcome of screening (FOBt) and diagnostic tests for 628 976 women who accepted bowel cancer screening

Bowel-screening outcome	Number of women (%)
Screening test outcome	
FOBt-positive	9133
FOBt-negative	619843
Attendance for further investigations of 9133 who were FOBt-positive	
Attended for diagnostic test	7911
Did not attend diagnostic test	1222
Diagnostic test results for 7911 who attended for further investigation	
Colorectal cancer	743
Colorectal adenoma	3056
Non-neoplastic condition only*	2214
No abnormality recorded	1881
No result from diagnostic tests	17
Abbreviation: FOBt=faecal occult blood testing. *That is, recorded abnormalities other than cancer or adenoma; includes diverticular disease, haemorrhoids, inflammatory bowel disease, and so on.	

recorded in the NHS Bowel Cancer Screening Programme database.

DISCUSSION

Our results illustrate the potential of using linked routinely collected and cohort study data in investigating associations between lifestyle factors and participation in a national cancer-screening programme. Women who were obese, current smokers, of non-White ethnicity and from more deprived areas were less likely to take part in bowel cancer screening in England; these factors were also associated with an increased risk of FOBt positivity and of having screen-detected colorectal adenoma, but not of screen-detected colorectal cancer.

While not strongly related to acceptance or FOBt positivity, ever use of menopausal HT was associated with a decreased risk of adenoma and of colorectal cancer.

Our findings for factors affecting participation in bowel cancer screening add to the evidence currently available. Studies of

Table 4. Adjusted^a RRs and 95% CIs for FOBt-positive result and screen-detected colorectal cancer and adenoma in screened women

	FOBt positive (N=9133)		Colorectal cancer (N=743)		Colorectal adenoma (N=3056)	
	n cases	RR (95% CI)	n cases	RR (95% CI)	n cases	RR (95% CI)
Socioeconomic level (tertiles)						
Least deprived	2840	1.00	274	1.00	943	1.00
Medium	3028	1.08 (1.03–1.14)	237	0.90 (0.75–1.07)	1028	1.11 (1.01–1.21)
Most deprived	3202	1.21 (1.14–1.27)	229	0.98 (0.82–1.17)	1067	1.22 (1.12–1.34)
Ethnic group						
White	8595	1.00	722	1.00	2910	1.00
Black	75	1.86 (1.49–2.33)	3	Insufficient data	21	1.61 (1.06–2.49)
South Asian	149	3.45 (2.94–4.05)	2	Insufficient data	34	2.49 (1.74–3.50)
Smoking status						
Never	4216	1.00	367	1.00	1364	1.00
Past	2744	1.16 (1.11–1.22)	231	1.15 (0.97–1.35)	907	1.18 (1.09–1.29)
Current	1649	1.29 (1.22–1.37)	110	1.03 (0.83–1.28)	621	1.53 (1.38–1.68)
Body mass index (kg m⁻²)						
<25	3292	1.00	312	1.00	1120	1.00
25–29	3164	1.31 (1.24–1.37)	261	1.12 (0.95–1.33)	1124	1.37 (1.26–1.49)
30+	2172	1.93 (1.83–2.04)	130	1.22 (0.99–1.50)	665	1.77 (1.61–1.95)
Full-term pregnancy						
Never	1014	1.00	86	1.00	356	1.00
Ever	8105	0.88 (0.82–0.93)	654	0.85 (0.68–1.07)	2698	0.84 (0.75–0.94)
Oral contraceptive use						
Never	3290	1.00	280	1.00	1159	1.00
Ever	5741	0.99 (0.95–1.04)	445	1.02 (0.87–1.19)	1875	0.93 (0.86–1.01)
HT use						
Never	3983	1.00	367	1.00	1442	1.00
Ever	5049	1.02 (0.98–1.06)	369	0.78 (0.68–0.91)	1583	0.87 (0.81–0.93)
Strenuous exercise (per week)						
<1	5542	1.00	448	1.00	1850	1.00
1+	3241	0.89 (0.85–0.93)	276	0.87 (0.74–1.01)	1099	0.89 (0.83–0.96)
Alcohol (g per week)						
<20	4885	1.00	381	1.00	1550	1.00
20+	4170	1.01 (0.97–1.05)	353	1.05 (0.91–1.22)	1484	1.13 (1.05–1.22)
Region						
South	4550	1.00	360	1.00	1526	1.00
Midlands	2007	0.92 (0.87–0.97)	175	1.03 (0.86–1.23)	634	0.86 (0.78–0.94)
North	2576	0.92 (0.87–0.96)	208	0.97 (0.82–1.16)	896	0.94 (0.86–1.02)
Abbreviations: CI = confidence interval; FOBt = faecal occult blood testing; HT = hormone therapy for menopause; RR = relative risk.						
^a Adjusted for age at invitation and calendar year categories, and all other factors listed above as appropriate.						

Table 5. Adjusted^a RRs and 95% CIs for acceptance of diagnostic test in 9133 women with positive FOBt

	n cases accepted/invited	RR (95% CI)
	7911/9133 (87%)	
Socioeconomic level (tertiles)		
Least deprived	2484/2840 (88%)	1.00
Medium	2640/3028 (87%)	1.00 (0.98–1.02)
Most deprived	2735/3202 (85%)	0.99 (0.97–1.01)
Ethnic group		
White	7483/8595 (87%)	1.00
Black	66/75 (88%)	1.01 (0.93–1.10)
South Asian	120/149 (81%)	0.93 (0.86–1.01)
Smoking status		
Never	3693/4216 (88%)	1.00
Past	2377/2744 (87%)	0.99 (0.97–1.00)
Current	1391/1649 (84%)	0.96(0.94–0.99)
Body mass index (kg m⁻²)		
<25	2848/3292 (87%)	1.00
25–29	2777/3164 (88%)	1.02 (0.99–1.04)
30+	1856/2172 (86%)	0.99 (0.97–1.01)
Full-term pregnancy		
Never	872/1014 (86%)	1.00
Ever	7026/8105 (87%)	1.01 (0.98–1.04)
Oral contraceptive use		
Never	2837/3290/ (86%)	1.00
Ever	4984/5741 (87%)	1.00 (0.98–1.02)
HT use		
Never	3448/3983 (87%)	1.00
Ever	4374/5049 (87%)	1.00 (0.98–1.02)
Strenuous exercise (per week)		
<1	4764/5542 (86%)	1.00
1+	2858/3241 (88%)	1.02 (1.00–1.04)
Alcohol (g per week)		
<20	4188/4885 (86%)	1.00
20+	3657/4170 (88%)	1.02 (1.01–1.04)
Region		
South	3949/4550 (87%)	1.00
Midlands	1738/2007 (87%)	1.00 (0.98–1.02)
North	2224/2576 (86%)	1.00 (0.97–1.03)
Abbreviations: CI = confidence intervals; FOBt = faecal occult blood testing; HT = hormone therapy; RR = relative risks.		
^a Adjusted by age at invitation and calendar year categories, and all other factors listed above as appropriate.		

population-level data from UK bowel-screening programmes have consistently found lower uptake of the FOB screening test among those living in more deprived and more ethnically diverse areas, in younger than in older people and in men than in women; in screening rounds later than the first, participation is also strongly linked to past screening history (Steele *et al*, 2010; von Wagner *et al*, 2011; Moss *et al*, 2012; Lo *et al*, 2014). Our findings are consistent with these studies and provide the first direct evidence on individual-level ethnic group and bowel cancer-screening uptake in the United Kingdom. Similar associations of age, sex and deprivation with nonparticipation have been reported for FOBt-based bowel cancer-screening programmes elsewhere in Europe (Frederikson *et al*, 2010; Blom *et al*, 2014) and in Australia (Weber *et al*, 2008) and in relation to uptake of screening for other conditions (Moser *et al*, 2009; Lo *et al*, 2013).

Evidence on other characteristics related to uptake of FOBt is sparse; to our knowledge, ours is the first study to link prospectively collected information on individual lifestyle characteristics with data from a population-based screening programme. There is some evidence from case-control studies with retrospective ascertainment of individual characteristics that

smokers are less likely than non-smokers to attend bowel cancer screening (Senore *et al*, 2010; van Dam *et al*, 2013); however, such studies are likely to be affected by response rate and recall biases. In a cross-sectional analysis of recruitment data reported by participants in the 45 and up Australian cohort, a recent history of FOBt screening was less common in current smokers, the obese and those with a sedentary lifestyle (Weber *et al*, 2008). Among women accepting screening, we found considerable variation in the risk of being FOBt-positive, with deprivation, Non-White ethnicity, smoking and obesity all associated with an increased risk. All of these factors were also associated with an increased risk of having screen-detected colorectal adenoma, but not of having screen-detected colorectal cancer. The risk of screen-detected colorectal cancer was reduced in ever users of menopausal hormones and in women who were physically active. This echoes findings from epidemiological studies of colorectal cancer (Green *et al*, 2012; Robsahm *et al*, 2013); however, we cannot easily interpret our findings for screen-detected cancer in terms of aetiology, as in these analyses potential risk factors can be related to screening test uptake and performance, and hence to the likelihood of undergoing a diagnostic test, as well as to the risk of underlying disease. Our analyses were also limited by the relatively small number of cases of screen-detected cancer in some subgroups. The prospective collection of exposure data is a strength of this study; a potential limitation is that information on exposure variables was collected several years before the invitation to bowel cancer screening.

We found that among those with a positive FOB test, smokers and those of South Asian ethnicity were somewhat less likely to go on to have a diagnostic test (usually colonoscopy) within the screening programme. Little is known about who chooses not to pursue diagnostic testing after a positive screening test, and why. Population-level studies do not show much variation by age, sex or deprivation (Morris *et al*, 2012; Ferrat *et al*, 2013); for screening rounds later than the first, screening history is associated with uptake of colonoscopy (Ferrat *et al*, 2013; Lo *et al*, 2014). In this study 13% of those with a positive FOBt did not receive diagnostic testing within the screening programme; this is consistent with rates of non-uptake of colonoscopy of 10–20% reported for FOBt-based bowel-screening programmes in the United Kingdom (Morris *et al*, 2012; Moss *et al*, 2012; Lo *et al*, 2014) and elsewhere, including in randomised trials (Hewitson *et al*, 2008).

Uptake of bowel cancer screening in our study population (70%) was greater than that reported by the screening programme for all women in England (54%; Logan *et al*, 2012); this is not surprising, since Million Women Study participants were recruited via the NHS screening programme for breast cancer and would be expected to be more likely than average to take part in screening for other cancer types. It is however noteworthy, and consistent with other findings (Lo *et al*, 2013), that even among this group, almost a third of those invited did not participate in the bowel cancer-screening programme. The higher uptake of screening in this study compared with the general population is, however, unlikely to affect comparisons within the cohort of factors affecting uptake of screening or its outcomes. Of the women in our study who attended for diagnostic testing, some 9% were diagnosed with colorectal cancer, very similar to the national figure for women of 8%.

In summary, linkage of data from a large population-based bowel cancer-screening programme to prospectively collected personal data in a large cohort provides a powerful way of identifying factors associated with participation and outcomes of screening. Deprivation, South Asian and Black ethnicity, smoking and obesity were associated with reduced participation in the screening programme. These factors were also associated with an increased risk of being FOBt-positive and of having colorectal adenoma, but were not strong predictors of screen-detected colorectal cancer risk.

ACKNOWLEDGEMENTS

This study was funded by Cancer Research UK, UK Medical Research Council, National Health Service Bowel Cancer Screening Programme.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Blom J, Kilpeläinen S, Hultcrantz R, Törnberg S (2014) Five-year experience of organized colorectal cancer screening in a Swedish population—increased compliance with age, female gender, and subsequent screening round. *J Med Screen* **21**(3): 144–150.
- Ferrat E, Le Breton J, Veerabudun K, Bercier S, Brixi Z, Khoshnood B, Paillaud E, Attali C, Bastuji-Garin S (2013) Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test. *Br J Cancer* **109**(6): 1437–1444.
- Frederiksen BL, Jørgensen T, Brasso K, Holten I, Osler M (2010) Socioeconomic position and participation in colorectal cancer screening. *Br J Cancer* **103**(10): 1496–1501.
- Gathani T, Ali R, Balkwill A, Green J, Reeves G, Beral V, Moser KA. Million Women Study Collaborators (2014) Ethnic differences in breast cancer incidence in England are due to differences in known risk factors for the disease: prospective study. *Br J Cancer* **110**(1): 224–229.
- Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, Beral V (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. *Int J Cancer* **130**(10): 2387–2396.
- Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* **103**(6): 1541–1549.
- Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C (2014) Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. *Gut* **64**(2): 282–291.
- Lo SH, Waller J, Wardle J, von Wagner C (2013) Comparing barriers to colorectal screening with barriers to breast and cervical screening: a population based survey of screening age women in Great Britain. *J Med Screen* **20**: 73–79.
- Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. English Bowel Cancer Screening Evaluation Committee (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. *Gut* **61**(10): 1439–1446.
- Million Women Study Collaborative Group (1999) The Million Women Study: design and characteristics of the study population. *Breast Cancer Res* **1**(1): 73–80.
- Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* **362**(9382): 419–427.
- Morris S, Baio G, Kendall E, von Wagner C, Wardle J, Atkin W, Halloran SP, Handley G, Logan RF, Obichere A, Rainbow S, Smith S, Snowball J, Raine R (2012) Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme. *Br J Cancer* **107**(5): 765–771.
- Moser K, Patnick J, Beral V. (2009) Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data. *Br Med J* **338**: b2025.
- Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, Ramsell P, Patnick J, Weller DP. (2012) Performance measures in three rounds of the English bowel cancer screening pilot. *Gut* **61**(1): 101–107.
- Robsahm TE, Aagnes B, Hjartaker A, Langseth H, Bray FI, Larsen IK. (2013) Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. *Eur J Cancer Prev* **22**(6): 492–505.
- Senore C, Armaroli P, Silvani M, Andreoni B, Bisanti L, Marai L, Castiglione G, Grazzini G, Taddei S, Gasperoni S, Giuliani O, Malfitana G, Marutti A, Genta G, Segnan N (2010) Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation. *Am J Gastroenterol* **105**(1): 188–198.
- Steele RJ, Kostourou I, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA, Fraser C (2010) Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening. *Br Med J* **341**: e5531.
- The Lancet (2014) Toward better control of colorectal cancer. *Lancet* **383**(9927): 1437.
- Townsend P, Phillimore P, Beattie A (1988) *Health and Deprivation: Inequality and the North*. Croon Helm: London.
- van Dam L, Korfage IJ, Kuipers EJ, Hol L, van Roon AH, Reijerink JC, van Ballegooijen M, van Leerdam ME (2013) What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy? *Eur J Cancer* **49**(10): 2321–2330.
- von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J (2011) Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. *Int J Epidemiol* **40**(3): 712–718.
- Weber MF, Banks E, Ward R, Sitas F (2008) Population characteristics related to colorectal cancer testing in New South Wales, Australia: results from the 45 and Up Study cohort. *J Med Screen* **15**(3): 137–142.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.